# Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft

> **NCT00067041** · PHASE2,PHASE3 · TERMINATED · sponsor: **United Therapeutics** · enrollment: 30 (—)

## Conditions studied

- Peripheral Vascular Disease

## Interventions

- **DRUG:** Remodulin (treprostinil sodium) Injection

## Key facts

- **NCT ID:** NCT00067041
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-03
- **Primary completion:** 2003-12
- **Final completion:** 2003-12
- **Target enrollment:** 30 (—)
- **Last updated:** 2013-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00067041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00067041, "Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00067041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*